Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. by Magherini, Francesca et al.
ORIGINAL PAPER
Exploring the biochemical mechanisms of cytotoxic gold
compounds: a proteomic study
Francesca Magherini • Alessandra Modesti • Luca Bini • Michele Puglia •
Ida Landini • Stefania Nobili • Enrico Mini • Maria Agostina Cinellu •
Chiara Gabbiani • Luigi Messori
Received: 23 October 2009 / Accepted: 28 December 2009 / Published online: 29 January 2010
 SBIC 2010
Abstract We have recently shown that a group of struc-
turally diverse gold compounds are highly cytotoxic toward
a panel of 36 human tumor cell lines through a variety of
biochemical mechanisms. A classic proteomic approach is
exploited here to gain deeper insight into those mecha-
nisms. This investigation is focused on Auoxo6, a novel
binuclear gold(III) complex, and auranofin, a clinically
established gold(I) antiarthritic drug. First, the 72-h cyto-
toxicity profiles of Auoxo6 and auranofin were determined
against A2780 human ovarian carcinoma cells. Subse-
quently, protein extraction from gold-treated A2780 cells
sensitive to cisplatin and 2D gel electrophoresis separation
were carried out according to established procedures.
Notably, both metallodrugs caused relatively modest
changes in protein expression in comparison with controls
as only 11 out of approximately 1,300 monitored spots
showed appreciable quantitative changes. Very remarkably,
six altered proteins were in common between the two
treatments. Eight altered proteins were identified by mass
spectrometry; among them was ezrin, a protein associated
with the cytoskeleton and involved in apoptosis. Interest-
ingly, two altered proteins, i.e., peroxiredoxins 1 and 6, are
known to play crucial roles in the cell redox metabolism.
Increased cleavage of heterogeneous ribonucleoprotein H
was also evidenced, consistent with caspase 3 activation.
Overall, the results of the present proteomic study point out
that the mode of action of Auoxo6 is strictly related to that
of auranofin, that the induced changes in protein expression
are limited and selective, that both gold compounds trigger
caspase 3 activation and apoptosis, and that a few affected
proteins are primarily involved in cell redox homeostasis.
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Introduction
In the past few decades considerable efforts were made in
the search of new metal-based anticancer agents that might
display innovative mechanisms of action and, thus offer
significant pharmacological advantages over the clinically
established antitumor platinum drugs (i.e., cisplatin, carbo-
platin, and oxaliplatin). Accordingly, several new platinum
and non-platinum compounds were prepared, characterized,
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and evaluated as potential cytotoxic and antitumor drugs
[1, 2].
In recent years research has increasingly focused on
gold(III) compounds as anticancer drug candidates because
gold(III) complexes typically display the same electronic
configuration (d8) and similar structural and reactivity
features of platinum(II) complexes (in particular a strong
preference for square-planar geometry and a rather favor-
able kinetic profile) [3]. Accordingly, our laboratories have
developed a variety of structurally diverse gold(III) com-
pounds as potential chemotherapeutic leads [4]. We pre-
viously reported that one of these complexes, namely, the
binuclear gold(III) complex Auoxo6, manifests very
encouraging cytotoxic properties in vitro and constitutes a
new promising chemotherapeutic lead [5, 6].
In the present study we adopted a classic proteomic
strategy to further investigate the mode of action of Au-
oxo6 in contrasting cancer cell growth. The behavior of
Auoxo6 is compared with that of auranofin, a gold(I)
antiarthritic drug, endowed with significant cytotoxic
properties in vitro (but not in vivo) [7]. Auranofin was
chosen as a control compound since it is a typical gold(I)
drug in clinical use and a lot is known about its bio-
chemical effects at the cellular level [8, 9]. The chemical
structures of Auoxo6 and auranofin are shown in Fig. 1.
Previous studies showed that cytotoxic gold(III) com-
pounds are able to induce cell death through apoptosis [10,
11]. However, for most gold compounds, apoptosis seems
to be essentially triggered by direct mitochondrial damage,
and is not the consequence of an initial DNA lesion, as in
the case of cisplatin. Within this frame, the pivotal role of
thioredoxin reductase as a probable target for cytotoxic
gold compounds was highlighted [12]. In particular, it
seems very likely that a strong inhibition of mitochondrial
thioredoxin reductase may eventually lead to a deep
alteration of the mitochondrial membrane potential, to
release of cytochrome c, and to consequent triggering of
apoptosis [12]. Such a type of ‘‘mitochondrial mechanism’’
was also proposed for gold(III) porphyrins [11], on which
detailed proteomic studies were recently carried out, and
for auranofin and a few related gold(I) compounds [13].
The relatively recent discipline of proteomics is mainly
concerned with the analysis and the characterization of the
protein products of the genome, known as the ‘‘proteome’’
[14, 15]. The aim of proteomics also includes the investi-
gation of protein cellular activities and functions, and the
analysis of the flow of information within the cell. A large
part of this information is provided by several protein
networks, organized in discrete signal transduction path-
ways, which control ultimately cell apoptosis. Proteomic
profiling, therefore, offers a good opportunity to identify
the proteins that mediate the apoptotic pathways when cells
are treated with cytotoxic agents.
Notably, a few examples already exist in the literature
where proteomic methods have been successfully utilized
for investigating the mode of action of anticancer metal-
lodrugs [16]. The mechanisms of action of anticancer
metallodrugs are usually very complicate and variegate
owing to the high reactivity of these compounds toward
biomolecules, to their being (in most cases) prodrugs (thus
undergoing large chemical transformations within the
biological milieu), and to the large differences in electronic
structure and reactivity existing among the various metal
centers. The intrinsic high reactivity of metallodrugs typi-
cally leads to the occurrence of numerous interactions with
a multitude of biomolecules, of which only a few are
biochemically and functionally relevant. This situation
may render the target identification and validation pro-
cesses for metallodrugs very troublesome.
Some previous attempts to use classic proteomic meth-
ods to reveal the mechanism of action of metal-based
cytotoxic drugs were carried out. In particular, the pro-
teomic responses of cancer cells to platinum compounds
were analyzed through a few studies. Yim et al. [17]
examined differential protein expression in cisplatin-trea-
ted HeLa cervical carcinoma cells and found 21 altered
proteins, of which 12 were upregulated and nine were
downregulated. Notably, these authors showed that cis-
platin induced a marked downregulation of nuclear factor
jB; in addition, activation of both death-receptor-mediated
and mitochondria-mediated apoptotic pathways was docu-
mented. Yao et al. [18] carried out comparative proteomic
studies of colon cancer cells in response to oxaliplatin
treatment and highlighted a number of proteins (around 20)
that were simultaneously altered in three distinct colon
cancer cell lines, namely, HT29, SW620, and LoVo. These
overlapping proteins were identified and found to take part
in many cellular processes, such as apoptosis, signal
transduction, transcription and translation, cell structural
organization, and metabolism. Notably, one of these altered
proteins was ezrin. In turn, Che et al. [19] used 2D elec-
trophoresis based proteomic technology to investigate the
protein expression profiles of human nasopharyngeal
carcinoma SUNE1 cells upon treatment with gold(III)
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Fig. 1 Auranofin (I) and Auoxo6 (II)
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porphyrin 1a [20]. Relevant changes in the expression of a
number of proteins engaged in redox metabolism, in the
mitochondrial functions, and in apoptosis pathways were
detected. In particular, voltage-dependent anion channel
(VDAC) 1 was found to be highly upregulated. VDAC 1 is
a mitochondrial outer-membrane channel protein which
functions as a main pathway for the movement of various
substances in and out of the mitochondria [21] and is
considered to be a component of the permeability transition
pore oligoprotein complex. These large alterations of
VDAC expression suggested that mitochondria could be a
primary target for gold(III) porphyrin 1a. Overall, the
above-mentioned papers document the feasibility and the
effectiveness of a classic proteomic approach.
Moreover, it is worth noting here that in the case of
metallodrugs additional proteomic experiments may be
devised that are centered on the metal and are principally
aimed at investigating metal distribution patterns within the
proteome (metallomics) [22–24]. These investigative
approaches, relying on the selective tagging of the metal-
lodrug or of the metal itself within 1D or 2D gels through
highly sensitive methods, allow in principle the identifi-
cation of all those proteins capable of binding the metal-
lodrug of interest. Indeed, it is very likely that the effective
targets for the metallodrug investigated are to be searched
for among the proteins with which the metal is tightly
associated. A few notable examples of this kind of strategy
are available in the recent literature [25–28]. Nowadays,
metallomic studies may take particular advantage of the
use of very sensitive hyphenated methods as extensively
documented by Becker et al. [29] and by other research
groups in a few recent papers and reviews.
We report here the results of a classic proteomic study
on the cellular effects of two prototypical cytotoxic gold
compounds, i.e., Auoxo6 and auranofin. Upon comparing
the proteomic profiles of A2780 cancer cells treated with
Auoxo6 or auranofin with those of controls, we could
identify a small number of differentially expressed proteins
by mass spectrometry (MS). In turn, detailed functional
analyses of the few altered proteins provide valuable
insight into the possible biochemical mechanisms that are
elicited by these two gold compounds, leading in both
cases to apoptotic cancer cell death.
Materials and methods
Materials and reagents
Auoxo6 was synthesized as described in [30], and auran-
ofin was purchased from Vinci Biochem. All other chem-
icals were of analytical grade. RPMI 1640 cell culture
medium, fetal calf serum, and phosphate-buffered saline
were purchased from Celbio (Milan, Italy); sulforhodamine
B (SRB) was from Sigma (Milan, Italy).
Cell lines and cell culture
The cytotoxic properties of Auoxo6 and auranofin were
analyzed in vitro according to the standard procedure
described by Skehan et al. [31] working on the A2780
ovarian carcinoma human cell line either sensitive (A2780/S)
or resistant (A2780/R) to cisplatin. This method estimates the
residual cell number after drug treatment on the basis of
quantitative determination of total cellular proteins after
staining with SRB. Exponentially growing cells were inoc-
ulated into 96-well microtiter plates. After 24 h, the medium
was removed and replaced with fresh medium containing
an appropriate drug concentration for a continuous drug
exposure of 72 h.
Then, cells were fixed in situ by 10% cold trichloro-
acetic acid and stained by SRB solution at 0.4% (w/v) in
1% acetic acid. After staining, unbound dye was removed
by washing with 1% acetic acid and the plates were air-
dried. Bound stain were subsequently solubilized with
10 mM tris(hydroxymethyl)aminomethane (Tris), and the
absorbance was read on an automated plate reader at a
wavelength of 540 nm. The above-mentioned assay
enables determination of the drug concentration needed to
inhibit cell growth by 50% (IC50).
Sample preparation and 2D gel electrophoresis
Whole protein extracts were obtained from A2780/S cells
and from A2780/S cells treated with Auoxo6 and aurano-
fin. Briefly, the cells were seeded in tissue-culture plates at
5 9 104 cells/mL (total volume 30 mL) and incubated
overnight, then exposed to concentrations of the study
compounds equal to 72-h-exposure IC50 values for 24 h. At
the end of the incubation the cells were washed with
phosphate-buffered saline, then were scraped in RIPA
buffer [50 mM Tris–HCl pH 7.0, 1% NP-40, 150 mM
NaCl, 2 mM ethylene glycol bis(2-aminoethyl ether)tetra-
acetic acid, 100 mM NaF] containing a cocktail of protease
inhibitors (Sigma). The cells were sonicated (10 s) and
protein extracts were clarified by centrifugation at 8,000g
for 10 min. Proteins were precipitated following a
chloroform/methanol protocol [32] and the pellet was
resuspended in 8 M urea, 4% 3-[(3-cholamidopropyl)
dimethylammonio]propanesulfonic acid (CHAPS), and
20 mM dithiothreitol (DTT). Three independent experi-
ments were performed and each sample was run in
triplicate to assess biological and analytical variation.
Isoelectric focusing (first dimension) was carried out on
nonlinear wide-range immobilized pH gradients (IPGs; pH
3.0–10; 18-cm-long IPG strips; GE Healthcare, Uppsala,
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Sweden) and achieved using an EttanTM IPGphorTM sys-
tem (GE Healthcare, Uppsala, Sweden). Analytical-run
IPG strips were rehydrated with 60 lg of total proteins in
350 lL of lysis buffer and 0.2% carrier ampholyte for 1 h
at 0 V and for 8 h at 30 V, at 20 C. The strips were
focused at 20 C according to the following electrical
conditions: 200 V for 1 h, from 300 to 3,500 V in 30 min,
3,500 V for 3 h, from 3,500 to 8,000 V in 30 min, and
8,000 V until a total of 80,000 V/h was reached. For pre-
parative gels, 18-cm IPG strips (pH 3–10 NL) were rehy-
drated overnight for 20 h at room temperature in 350 lL of
rehydration buffer containing 8 M urea, 2% w/v CHAPS,
0.5% DTT, and 0.5% IPG buffer with the same pH range as
the Immobiline DryStrips and a trace of bromophenol blue.
Rehydrated strips were rinsed in double-distilled water to
remove urea crystals. Samples (up to 1 mg) were cup-
loaded near the anode of the IPG strips using an Ettan
IPGphor cup-loading manifold (GE Healthcare) according
to the manufacturer’s protocol.
After focusing, analytical and preparative IPG strips
were equilibrated for 12 min in 6 M urea, 30% glycerol,
2% sodium dodecyl sulfate, 2% DTT in 0.05 M Tris–HCl
buffer, pH 6.8, and subsequently for 5 min in the same
urea/sodium dodecyl sulfate/Tris–HCl buffer solution
where DTT was substituted with 2.5% iodoacetamide. The
second dimension was carried out on 9–16% polyacryl-
amide linear gradient gels (18 cm 9 20 cm 9 1.5 mm) at
10 C and 40 mA per gel constant current until the dye
front reached the bottom of the gel. Analytical gels were
stained with ammoniacal silver nitrate as previously
described [33]; MS-preparative gels were stained with
colloidal Coomassie [34].
Image analysis and statistics
Images of the gels were acquired with an Epson expres-
sion 1680 PRO scanner. For each condition, three bio-
logical replicates were performed and only the spots
present in all the replicates were taken into consideration
for subsequent analysis. Computer-aided 2D image anal-
ysis was carried out using ImageMaster 2D Platinum
version 6.0 (GE Healthcare). The relative spot volume
calculated as %V (Vsingle spot/Vtotal spots, where V is the
integration of the optical density over the spot area) was
used for quantitative analysis io decrease experimental
errors. The normalized intensity of the spots on replicate
2D gels was averaged and the standard deviation was
calculated. The mean values were compared among the
three different conditions (control, auranofin-treated cells,
and Auoxo6-treated cells) by analysis of variance fol-
lowed by Tukey’s post hoc multiple comparisons using
the Graphpad Prism4 program. P \ 0.05 was considered
statistically significant.
Protein identification by mass spectrometry
Protein identification was carried out by peptide mass fin-
gerprinting on an Ettan matrix-assisted laser desorption/
ionization (MALDI) time of flight (TOF) Pro mass spec-
trometer (Amersham Biosciences), as previously described
[35, 36]. Electrophoretic spots, visualized by a colloidal
Coomassie staining protocol, were manually excised,
destained, and acetonitrile-dehydratated. Successively,
they were rehydratated in trypsin solution, and in-gel
protein digestion was performed by an overnight incuba-
tion at 37 C. From each excised spot, 0.75 lL of recov-
ered digested peptides was prepared for MALDI-TOF MS
by spotting them onto the MALDI target, allowing them to
dry, and then mixing them with 0.75 lL of matrix solution
[saturated solution of a-cyano-4-hydroxycinnamic acid in
50% (v/v) acetonitrile and 0.5% (v/v) trifluoroacetic acid].
After application of the matrix to the dried sample and
drying, tryptic peptide masses were acquired. Mass-fin-
gerprinting searching was carried out in the NCBInr and
Swiss-Prot databases using Mascot (Matrix Science, Lon-
don, UK, http://www.matrixscience.com). Protein identifi-
cation was achieved on the basis of corresponding
experimental and theoretical peptide-fingerprinting pat-
terns. A mass tolerance of 100 ppm was allowed and only
one missed cleavage site accepted. Alkylation of cysteine
by carbamidomethylation was assumed as a fixed modifi-
cation, whereas oxidation of methionine was considered a
possible modification. The criteria used to accept identifi-
cations included the extent of sequence coverage, the
number of matched peptides, and a probabilistic score, as
reported in Table 2.
Tryptic digests that did not produce MALDI-TOF
unambiguous identifications were subsequently acidified
with 2 lL of a 1% trifluoroacetic acid solution, and then
subjected to electrospray ionization (ESI)–ion trap MS/MS
peptide sequencing using an LCQ DECA ion trap mass
spectrometer (Thermo Finnigan, San Jose, CA, USA). With
use of ZIP-TIPTM pipette tips for sample preparation
(Millipore, Billerica, MA, USA), previously equilibrated in
50% acetonitrile solution and abundantly washed in 0.1%
trifluoroacetic acid, acidified samples were enriched.
Tryptic peptide elution from the ZIP-TIPTM matrix was
achieved with a 70% methanol and 0.5% formic acid
solution, and 3 lL of such concentrated sample solutions
was then loaded in the nanospray needle. MS/MS database
searching was performed by TurboSEQUEST (Thermo)
and Mascot MS/MS ion search software (http://www.
matrixscience.com) in the Swiss-Prot/TrEMBL or NCBInr
databases. The following criteria were applied: MS accu-
racy ±1.2 Da, MS/MS mass accuracy ±0.6 Da, peptide
precursor charge 2?, monoisotopic experimental mass
values, trypsin digestion with one allowed missed cleavage,
576 J Biol Inorg Chem (2010) 15:573–582
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fixed carbamidomethylation of cysteine, and variable oxi-
dation of methionine.
Results
Antiproliferative effects of the chosen gold drugs
toward A2780 cells
At first, the cytotoxic effects of auranofin on A2780 human
ovarian carcinoma cells, either sensitive (A2780/S) or
resistant (A2780/R) to cisplatin, were measured according
to standard methods. On the ground of the SRB assay
results, IC50 values of 0.5 and 0.3 lM were determined for
auranofin on the sensitive and resistant cell lines, respec-
tively, after 72-h drug exposure. In turn, the measured IC50
values for Auoxo6 were found to be perfectly consistent
with those previously reported by Casini et al. [5] (1.8 and
4.9 lM for A2780/S and A2780/R, respectively). We also
observed that very limited cell death was evident, for both
compounds, at 24 h, this rendering a classic proteomic
approach well feasible. Remarkably, the IC50 values
obtained with auranofin and Auoxo6 closely match those
recently determined for the same compounds on a 36 cell
line panel [37].
Proteomic profiles of control and gold-treated
cancer cells
To investigate in detail the mechanisms of cell death
induced by these gold drugs, protein profiles of control,
Auoxo6-treated, and auranofin-treated A2780 cells were
studied by comparative proteomic analysis. A2780/S cells
were treated, for 24 h, with auranofin and Auoxo6, at their
72-h-exposure IC50 concentrations (0.5 and 1.8 lM,
respectively), and protein extracts were subsequently pre-
pared, as described in ‘‘Materials and methods.’’ Then,
proteins were separated by 2D gel electrophoresis and the
resulting silver-stained gels were analyzed using the Im-
ageMaster 2D Platinum version 6.0. Representative 2D
silver-stained gels for control, Auoxo6–treated, and
auranofin-treated A2780/S cells are shown in Fig. 2. An
average of about 1,300 protein spots was separated on the
gels. To obtain statistically significant results, each protein
sample was run in triplicate. The box highlights a major
area where significant and consistent alterations of protein
Control cells
Auranofin treated cells
Auoxo 6 treated cells
A
J
C
B
D
E
F
H
I
K
G
A B
Mr kDa
200
10
pH 3 pH 10Non –linear IPG
Fig. 2 a Representative 2D gel images for control cells, auranofin-
treated cells, and Auoxo6-treated cells. b Representative gel image of
A2780 control cells. The box highlights a major area where significant
and consistent alterations of protein expression were identified Circles
and letters indicate differentially expressed proteins
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expression were identified. Circles and letters indicate
differentially expressed proteins as emerged from com-
parative gel analysis.
Remarkably, auranofin and Auoxo6 treatments just
caused very modest perturbations of the protein expression
profiles. Indeed, only a very limited number of proteins, of
the more than 1,300 monitored, showed appreciable
downregulation or upregulation. Comparative computer
analysis highlighted 11 meaningful variations between
treated cells and control cells. Proteins with at least a
1.5-fold (P \ 0.05) change in their expression level were
considered as ‘‘changed’’ and were selected for further
identification by MS. The locations of these protein spots are
marked with capital letters in the representative gel shown in
Fig. 2. The histograms in Fig. 3 illustrate the variation of
protein expression for both drug treatments in comparison
with untreated cells. As is evident from inspection of the
histograms, three spots (spots F, G, and I) manifest a pro-
nounced upregulation in both treated cells in comparison
with the control; in contrast, three spots (spots A, B, and C)
show a downregulation in both drug treatments. Finally four
spots (spots D, E, H, and J) show a significant variation only
when cells were treated with auranofin.
In Table 1 the quantitative data and the statistical
analyses for the protein spots whose intensity levels sig-
nificantly differed among A2780/S control cells and
auranofin- or Auoxo6-treated cells are reported. A total of
eight spots were successfully identified by MS.
Identification of differentially expressed proteins
in gold-treated cells
Table 2 summarizes the parameters obtained from data-
base-matching for protein identification, including protein
name, NCBI database access number, sequence cover-
age, Mascot score, peptide matched, theoretical and
experimental mass, and pI. In Fig. 4 an enlargement of
spots corresponding to the identified differentially expres-
sed proteins is shown with the corresponding changes in
expression rate. Among the proteins that we identified, by
MS, as upregulated in both auranofin- and Auoxo6-treated
cells are ezrin (spot G), associated with the cytoskeleton
[38], peroxiredoxin 1 (spot I), a peroxidase with a high
antioxidant efficiency implicated in regulating proliferation
[39], differentiation, and apoptosis, and fragments of the
heterogeneous nuclear ribonucleoprotein (spot F), which
provides the substrate for the processing events that pre-
cursor messenger RNA undergoes before becoming func-
tional [40]. This protein was also identified in spot A
corresponding to the full protein. Downregulation of his-
tidine triad nucleotide-binding protein 1 (Hint1; spot B), an
enzyme able to hydrolyze adenosine 50-monophosph-
oramidate substrates [41], of oeroxiredoxin 6 (spot H), and
of 3-hydroxyacyl-CoA dehydrogenase (spot J) functioning
in mitochondrial transfer RNA maturation, were also
observed [42].
Discussion
A2780 proteome responses to auranofin
and Auoxo6 treatments
A classic proteomic approach, relying on 2D gel electro-
phoresis coupled with MS, was implemented here to
identify altered proteins in the A2780/S human tumor cell
line, in response to Auoxo6 and auranofin treatments.
A total of 11 differentially expressed protein spots were
detected in both cell treatments. Eight of these spots were
successfully identified by MS. Not all spots could be
identified because of the relatively low protein concentra-
tions and of the sensitivity limitations of MS. Of the eight
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Fig. 3 Relative protein expression changes of auranofin-treated
(white bars) and Auoxo6-treated (gray bars) cells versus control
cells (black). Bars represent the mean ± the standard deviation of
spots’ volume percentage from three different experiments. Asterisks
indicate that the difference is statistically significant P \ 0.05.
The volume percentage is calculated as Vsingle spot/Vtotal spots
(V is the integration of the optical density over the spot area)
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identified proteins, six were altered in both cell treatments;
at variance, two proteins showed a significant change in
their expression levels only after auranofin treatment. It is
noteworthy that both treatments, though causing extensive
cell death at 72 h, induce very limited changes in the
proteome at 24 h. Such a situation is markedly different
from that found for cisplatin and for gold(III) porphyrin 1a
in previous studies [11, 19], where far more pronounced
and diffuse proteome alterations were detected, after 24 h.
Conversely, the fact that most affected proteins are in
Table 1 Quantitative data and statistical analyses of protein spots whose intensity levels significantly differed among A2780 control cells and
auranofin- and Auoxo6-treated cells
Spot Spot intensity (arbitrary unit) ANOVA Tukey’s post hoc multiple comparisons
A2780 control cells A2780 ? auranofin A2780 ? Auoxo6 Control versus
auranofin
Control versus
Auoxo6
Auranofin
versus Auoxo6
A 0.1392 ± 0.0148 0.0842 ± 0.0149 0.109 ± 0.0119 P = 0.0012 P \ 0.001 P \ 0.05 NS
B 0.1536 ± 0.0689 0.015241 ± 0.01236 0.017678 ± 0.018913 P = 0.002 P \ 0.01 P \ 0.01 NS
C 0.0584 ± 0.0115 0.03104 ± 0.0074 0.04054 ± 0.0048 P = 0.0038 P \ 0.01 P \ 0.05 NS
D 0.0706 ± 0.017626 0.17162 ± 0.0249 0.08515 ± 0.04376 P = 0.0025 P \ 0.01 NS P \ 0.01
E 0.0927 ± 0.0396 0.1817 ± 0.0574 0.129 ± 0.0215 P = 0.044 P \ 0.05 NS NS
F 0.0063 ± 0.031 0.0443023 ± 0.012644 0.0852521 ± 0.0147189 P \ 0.0001 P \ 0.01 P \ 0.001 P \ 0.01
G 0.0195 ± 0.0083 0.1312 ± 0.0694 0.1184 ± 0.0413 P = 0.0159 P \ 0.05 P \ 0.05 NS
H 0.1157 ± 0.0120 0.075 ± 0.0134 0.0971 ± 0.0109 P = 0.0139 P \ 0.05 NS NS
I 0.0059 ± 0.0041 0.0779 ± 0.0224 0.0715 ± 0.0163 P = 0.036 P \ 0.05 P \ 0.05 NS
J 0.1133 ± 0.0122 0.0728 ± 0.0079 0.089469 ± 0.0265 P = 0.028 P \ 0.05 NS NS
K 0.0164 ± 0.0043 0.0293 ± 0.0073 0.0148 ± 0.005 P = 0.0112 P \ 0.05 NS P \ 0.05
The mean values of individual parameters were compared among the three different conditions by analysis of variance (ANOVA) followed by
Tukey’s post hoc multiple comparisons using the GraphPad Prism4 program. P \ 0.05 was considered statistically significant
NS not significant
Table 2 Matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry (MS) and MS/MS analyses of proteins
whose levels significantly differed among control and treated cells
Spot Protein identity Accession
no.
MALDI-TOF MS MS/MS peptide sequence Theoretical
pI/molecular
mass (kDa)
Experimental
pI/molecular
mass (kDa)cScore
a Coverage
(%)b
No. of
matched
masses
A Heterogeneous nuclear
ribonucleoprotein
P31943 101 26 8 5.89/49.5 5.7/26.8
B Histidine triad nucleotide-
binding protein 1
P49773 129 71 7 6.43/13.9 6.4/16.1
C Triosephosphate isomerase
? high-mobility group
protein B1
P60174 ?
P09429
120
76
51%
27%
9
8
TATPQQAQEVHEK
VPADTEVVCAPPTAYIDFAR ?
GEHPGLSIGDVAK
6.45/26.9 ?
5.62/25.0
5.3/26.68 ?
5.3/26.68
F Heterogeneous nuclear
ribonucleoprotein
P31943 107 28 7 5.89/49.5 5.4/30.9
G Ezrin P15311 72 13 7 5.94/69.5 5.4/46.5
H Peroxiredoxin 6 P30041 66 22 5 LPFPIIDDR 6.00/25.1 6.2/27.1
I Peroxiredoxin 1 Q06830 90 32 5 TIAQDYGVLK 8.27/22.3 7.9/20.4
J 3-Hydroxyacyl-CoA
dehydrogenase type 2
Q99714 93 24 5 GLVAVITGGASGLGLATAER 7.87/27.1 7.7/25.9
a MS matching score greater than 65 was required for a significant MS hit
b Sequence coverage = (number of the identified residues/total number of amino acid residues in the protein sequence) 9 100%
c Based on the calculation using ImageMaster 2D Platinum
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common between the two treatments is highly suggestive
of an identical (or at least very similar) effect of both
Auoxo6 and auranofin against this cancer cell model.
Remarkably, the affected proteins participate in a variety of
cellular processes, such as cell structural organization,
defense against oxidative stress, transcription, translation,
and metabolism. More details on the functional roles of the
affected proteins are given next.
Functional roles of the identified proteins
Morphological changes accompanied by cytoskeleton
arrangement are considered as an hallmark of apoptosis
[43]; in the present study, according to the 2D electro-
phoresis maps and MS/MS analysis, we observed an
increase in the expression level of ezrin, a cytoskeleton
regulatory protein involved in cellular events such as pro-
liferation, cell migration, and apoptosis [44–46].
We also observed, upon Auoxo6 or auranofin treatment,
an increase in the fragmentation of the heterogeneous
nuclear ribonucleoprotein H; furthermore, we identified a
downregulation in the expression of the complete protein.
This protein is implicated in several steps of the precursor
messenger RNA processing and in cellular differentiation
[47]. Its overexpression was observed in primary carcino-
mas and metastases [48]; a downregulation of the protein
and an increase of its fragmentation could be the result of
drug treatments leading to the inhibition of cell prolifera-
tion and colony formation. Moreover, the overexpression
of heterogeneous nuclear ribonucleoprotein H leads to
production in HeLa cells of a proapoptotic alternative
splice variant of Bcl-x [Blc-x(S)] [49]. At the time point of
the Auoxo6 and auranofin treatments studied, no increased
apoptosis was observed. We observed that apoptosis occurs
at a later time point and that the increase of heterogeneous
nuclear ribonucleoprotein H levels just precedes this pro-
cess [50].
In the current study we found a reduced expression of
Hint1. It is a member of the evolutionarily conserved
family of histidine triad proteins that acts as a haplo-
insufficient tumor suppressor; the molecular mechanisms
for the tumor-suppressing activity are poorly defined.
Consistent with a tumor suppressor function, in the human
non-small-cell lung cancer cell line NCI-H522, an alter-
ation in Hint1 expression was observed and reintroduction
of Hint1 resulted in cell growth inhibition and reduced
tumorigenicity [51]. Reduced or lost expression of tumor
suppressor proteins is often associated with impaired
Auoxo 6
3-hydroxyacyl-CoA 
dehydrogenase type-2 (J)
Peroxinredoxin-1 (I)
Peroxinredoxin-6 (H)
Ezrin (G)
Heterogeneous nuclear 
ribonucleoprotein (F)
Triosephosphate
isomerase+High mobility 
group protein B1(C)
Histidine triad nucleotide-
binding protein1 (B)
Heterogeneous nuclear 
ribonucleoprotein (A)
AuranofinControl
Fig. 4 Magnified regions of triplicate 2D gel images of spots corresponding to the identified proteins. Spots of interest are indicated with circles,
with the corresponding protein names given on the left. In the column on the right the relative histograms are reported
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induction of apoptosis. Hint1 is involved in the regulation
of apoptotic pathways by inducing an upregulation of p53
expression coinciding with an upregulation of the proa-
poptotic factor Bax and a concomitant downregulation of
the apoptosis inhibitor Bcl-2. Hint1 appears to modulate
transcriptional regulation, cell cycle control, and induction
of apoptosis [52].
Also, we observed an increased expression pattern of
peroxiredoxin 1 in response to both treatments. In con-
trast, we found a reduced expression of peroxiredoxin 6
as a result of auranofin treatment. Peroxiredoxins are
increased in a number of cancers, including lung cancer
[53], and have been correlated to radioresistance and
resistance to cisplatin [54] The peroxiredoxins also
influence a variety of cellular processes that are sensitive
to reactive oxygen species and play a role in signal
transduction and gene expression related to alteration in
cellular reactive oxygen species levels [55]. In many
cases increased peroxiredoxin expression correlated to
chemoresistance; our results suggest that treatment with
both drugs, modifying the expression of peroxiredoxin,
disrupts total cellular redox homeostasis and induces
apoptosis. Peroxiredoxin II could be the focus of new
drugs for use in the treatment of cancer. It was previously
reported [56] that inactivation of the stress-activated
protein peroxiredoxin constitutes a promising approach to
the development of improved cancer treatments, and that
inhibitors of peroxiredoxin represent very good anticancer
drug candidates, especially in the role of chemosensitizers
or radiosensitizers.
Inferences on the molecular mechanisms
of Auoxo6 and auranofin
The results reported above contain some important impli-
cations concerning the possible mechanism of action of
Auoxo6 and auranofin, observed from the ‘‘point of view’’
of the cell. Previous studies had highlighted that Auoxo6, a
binuclear gold(III) compound developed in our laborato-
ries, manifests remarkable cytotoxic properties, with IC50
values falling in the low micromolar range [5]. Moreover,
Auoxo6 is characterized by a rather pronounced selectivity
in its cytotoxic properties toward a large panel of 36 cell
lines as reported earlier [37]. Owing to the still appreciable
oxidizing properties of the gold(III) center, it can be
assumed that Auoxo6 may undergo facile reduction and
cleavage, thus being a source of gold(I) species. Indeed,
ESI-MS interaction studies with model proteins strongly
supported this view [57].
More extensive and detailed knowledge is available on
auranofin and its biochemical and cellular effects. Indeed,
auranofin is a drug in clinical use, since 1978, for the
treatment of rheumatoid arthritis, and a large amount of
documentation now exists on it. In particular, it was shown
that this compound is strongly cytotoxic and propapoptotic
in vitro and that apoptosis is probably mediated by a direct
mitochondrial mechanism. Strong inhibition of thioredoxin
reductase by auranofin was demonstrated as well in a
number of studies [12].
Remarkably, the present proteomic investigation revealed
that both assayed gold compounds, though being highly
cytotoxic (at 72 h), produce rather limited changes in the
protein expression patterns at 24 h, implying that cell dam-
age, at least in the early phases, is quite selective and limited.
Also, it is of interest to stress that the patterns of induced
protein alterations are very similar in the two cases, pointing
out that the modes of action of these two compounds may
be nearly identical. This observation most likely implies that
Auoxo6, in the cellular milieu, is reduced to a gold(I) species
and that the mode of action of the latter species closely
matches that of auranofin. It was previously proposed that
strong inhibition of thioredoxin reductase might constitute
a peculiar feature of the cytotoxic mechanism of auranofin
and of several other gold-based compounds: Thus, it is well
conceivable that the gold(I) species resulting from Auoxo6
reduction might act as a strong inhibitor of thioredoxin
reductase and thus cause its proapoptotic effects.
The few proteins whose expression is affected by these
gold drugs deserve some final comments. The increase in
ezrin expression might be considered as an initial sign of
apoptosis as the apoptotic process is known to involve a
large rearrangement of the cytoskeleton and of cell mor-
phology. In turn, the observed alterations in peroxiredoxins
1 and 6, which are nicely consistent with previous obser-
vations on the cellular effects of a gold(III) porphyrin, are
strongly suggestive of a intense cellular response to drug-
induced oxidative stress. Moreover, the marked increase in
heterogeneous ribonucleoprotein H is indicative of caspase
3 activation.
It may be hypothesized that these gold drugs elicit a
significant intracellular oxidative stress that cells attempt to
counteract during the early phases of treatment by activa-
tion of intrinsic defense mechanisms; failure to counteract
oxidative stress will eventually cause apoptotic cell death.
Additional time course proteomic analyses are being
planned to better identify and characterize the proposed
sequence of intracellular events.
Concluding remarks
The results of this proteomic study point out that the mode
of action of Auoxo6 is very similar to that of auranofin,
strongly suggesting that Auoxo6 reduction to a gold(I)
species takes place within the biological milieu. Quite
unexpectedly, the perturbations in the protein expression
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patterns induced by both gold compounds, after 24-h
incubation, are limited and selective, far less pronounced
than those caused by other metallodrugs previously
investigated. Some of the affected proteins are primarily
involved in the intracellular redox homeostasis, implying
that cell damage is probably the consequence of severe
oxidative stress; pairwise, two proteins that are biomarkers
of apoptosis were found to be greatly perturbed. The value
of novel proteomic approaches to decipher the complex
biochemical and cellular mechanisms of anticancer me-
tallodrugs is further supported by the present investigation.
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